Search the Newsreel

GLUE|Monte Rosa Therapeutics Inc|Price:21.600|Chg%:-0.440

Monte Rosa Therapeutics Inc. (GLUE) is a clinical-stage biotechnology company developing novel molecular glue degraders. The article highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. Institutional ownership is high, and analysts have issued …

Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE

Exome Asset Management LLC has acquired a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) worth approximately $2.95 million, making it the 24th largest holding for the firm. Despite Monte Rosa missing recent earnings and revenue expectations, analysts have a "Moderate Buy" consensus with …

Monte Rosa Therapeutics Inc (GLUE) Cash Flow

This article provides a detailed cash flow statement for Monte Rosa Therapeutics Inc (GLUE), presenting quarterly and annual data for operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures. The piece also features a "FAQs" section clarifying what operating, …

Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE

Monte Rosa Therapeutics, Inc. (GLUE) generated $123.70 million USD in revenue last year, primarily from its Novel Small Molecule Precision Medicines segment, which accounted for $123.67 million USD. The majority of the revenue, $111.30 million USD, originated from Switzerland. This represents an increase from …

Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Monte Rosa Therapeutics Inc (GLUE), listing major individual shareholders and their proportions, as well as the types of shareholder entities. It also provides institutional shareholding data over several quarters and lists related ETFs that hold GLUE shares. …

Monte Rosa Therapeutics Market Sentiment

This article analyzes Monte Rosa Therapeutics (GLUE) market sentiment through analyst consensus, short interest, options flow, and insider activity. The consensus is "Overweight" with a price target of $24, but rising short interest and net insider selling indicate some bearish sentiment. The article also …

Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE

This article provides the "Price to sales forward" financial metric for Monte Rosa Therapeutics, Inc. (GLUE) on the Blue Ocean Alternative Trade System (BOATS) platform. The content primarily consists of navigation and boilerplate text from the TradingView platform, indicating the specific financial data point …

Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Allspring Global Investments Holdings LLC significantly increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 1,355.1% in the first quarter, now owning 392,227 shares valued at $6.45 million. Other institutional investors like Price T Rowe and Vanguard also boosted their holdings, with institutional …

Have Insiders Sold Monte Rosa Therapeutics Shares Recently?

The President of Monte Rosa Therapeutics, Markus Warmuth, recently sold US$220k worth of shares, representing only 2.3% of his total holding. No insider purchases have been recorded in the past year, and insider ownership is relatively low at 0.5%, leading to a cautious outlook …

Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE)

Markus Warmuth, President & CEO of Monte Rosa Therapeutics Inc (GLUE), sold 9,500 shares of the company on July 16, 2026, reducing his holdings to 585,038 shares. Over the past year, Warmuth has sold a total of 49,500 shares with no purchases, contributing to …

Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each

Monte Rosa Therapeutics CEO Markus Warmuth reported an open-market sale of 9,500 shares of Common Stock on July 16, 2026, at a weighted average price of $23.1809 per share. Following this transaction, Warmuth directly holds 585,038 shares. The sale was not conducted under a …

Form 4 Monte Rosa Therapeutics Inc For: 16 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Monte Rosa Therapeutics Inc. on July 16, 2026. Form 4 filings detail changes in beneficial ownership of securities by company insiders and are a matter of public record. The article itself is very …

Price to book forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE

This article provides a brief financial data point for Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), specifically its price to book forward value. The content indicates the market status as closed with no recent trades. The page is primarily a financial data display from TradingView, …

GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144

Markus Warmuth, a shareholder of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), has filed a Form 144 notice to sell 9,500 shares of common stock. The aggregate market value of these shares is approximately $220,218.55, and the sale is expected to occur around July 16, …

Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock

Jennifer Champoux, COO of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), sold 4,351 shares of common stock for $101,729 on July 15, 2026, as part of a pre-arranged trading plan. This sale followed a significant 317% surge in the company's stock over the past year, placing …

Monte Rosa Therapeutics (GLUE) COO trades 4,351 shares via option exercise

Monte Rosa Therapeutics' Chief Operating Officer, Jennifer Champoux, exercised stock options to acquire 4,351 shares at $3.98 per share and subsequently sold them at a weighted average price of $23.3808. These transactions, executed under a Rule 10b5-1 trading plan, resulted in a net sale …

Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position

Versant Venture Management LLC reduced its stake in Monte Rosa Therapeutics (GLUE) by 27.4% in the first quarter, but it remains their largest holding, comprising 37% of their portfolio. The firm still owns 3.18 million shares valued at $52.3 million. Institutional investors collectively own …

GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise

Jennifer Champoux, a security holder of Monte Rosa Therapeutics (NASDAQ: GLUE), plans to sell 4,351 shares of common stock with an aggregate market value of $101,729.86. This sale, facilitated through UBS Financial Services on NASDAQ, is linked to a cash-funded exercise of stock options …

Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build

T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings

What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today